Immuneering (IMRX) Other financing activities (2022 - 2026)
Immuneering (IMRX) posted quarterly Other financing activities of $10435.0 for Q1 2026, down 92.21% year-over-year from $133892.0 in Q1 2025, and up 100.04% quarter-over-quarter from -$24.6 million in Q4 2025.
Immuneering (IMRX) Other financing activities (2022 - 2026) Analysis & Trends
Immuneering's Other financing activities history runs 5 years deep, the most recent figure standing at $10435.0 for Q1 2026.
- In Q1 2026, Other financing activities fell 92.21% year-over-year to $10435.0; the TTM figure through Mar 2026 stood at $298453.0 (down 51.78% YoY), while the FY2025 annual figure was $421910.0, down 42.4% from the prior year.
- Other financing activities for Q1 2026 stood at $10435.0, up from -$24.6 million in the prior quarter.
- The five-year high for Other financing activities was $24.9 million in Q3 2025, with the low at -$24.6 million in Q4 2025.
- The 5-year median for Other financing activities is $87995.0 (2022), against an average of $119376.2.
- Peak annual rise in Other financing activities reached 7049.61% in 2025, while the deepest fall reached 6969.11% in 2025.
- Immuneering's Other financing activities stood at $42098.0 in 2022, then plunged by 81.39% to $7835.0 in 2023, then surged by 4466.76% to $357806.0 in 2024, then tumbled by 6969.11% to -$24.6 million in 2025, then soared by 100.04% to $10435.0 in 2026.
- Business Quant data shows IMRX's Other financing activities at $10435.0 in Q1 2026, -$24.6 million in Q4 2025, and $24.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,435.00 |
| Mar 31, 2026 | 10,435.00 |
| Dec 31, 2025 | -24.58 Mn |
| Dec 31, 2025 | -24.58 Mn |
| Sep 30, 2025 | 24.87 Mn |
| Sep 30, 2025 | 24.87 Mn |
| Mar 31, 2025 | 133,892.00 |
| Mar 31, 2025 | 133,892.00 |
| Dec 31, 2024 | 357,806.00 |
| Dec 31, 2024 | 357,806.00 |
| Sep 30, 2024 | -357,806.00 |
| Sep 30, 2024 | -357,806.00 |
| Jun 30, 2024 | 484,993.00 |
| Jun 30, 2024 | 484,993.00 |
| Mar 31, 2024 | 247,465.00 |
| Mar 31, 2024 | 247,465.00 |
| Dec 31, 2023 | 7,835.00 |
| Dec 31, 2023 | 7,835.00 |
| Sep 30, 2023 | 437,003.00 |
| Sep 30, 2023 | 437,003.00 |